Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Wroclaw – page 70

941 clinical trials in Wroclaw, Poland across 14 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Wroclaw at a glance
941
clinical trials
  • Research sites14
Type of trial
Recruitment status
Quick filters

941 trials in Wroclaw

Open in trial search

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study on the Effects of NMRA-335140 for Adults with Major Depressive Disorder

Not recruiting
Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Study on Long-term Safety and Effectiveness of NMRA-335140 for Patients with Major Depressive Disorder

Not recruiting
InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Study of Durvalumab and Tremelimumab for Patients with Limited Stage Small-Cell Lung Cancer After Chemoradiation Therapy

Not recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dextrose Bp
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Cardiac failure chronic

Not recruiting

Study on the Effects of AZD5462 for Patients with Stable Chronic Heart Failure

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azd5462
  • Sponsor:AstraZeneca AB

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness and Safety of EDP-938 for Adults with High-Risk Respiratory Syncytial Virus (RSV) Infection

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zelicapavir
  • Sponsor:Enanta Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Belantamab Mafodotin with Pomalidomide and Dexamethasone to Bortezomib with Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Glaxosmithkline Research & Development Limited

Multiple sclerosis relapse

Not recruiting

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Wroclaw

What the registry says about research in the country

01 Respiratory Diseases

Innovative clinical trials focusing on respiratory viral infections, including studies of vaccines against RSV and human metapneumovirus in older adults. Research includes evaluation of novel immunization approaches for influenza prevention and lower respiratory tract infections.

  • RSV vaccine development
  • Influenza prevention
  • Respiratory infection management
02 Dermatological Conditions

Comprehensive research into plaque psoriasis and related conditions, examining new therapeutic approaches including biologics and oral medications. Studies focus on both moderate to severe cases and specific manifestations like genital psoriasis.

  • Psoriasis treatment innovations
  • Psoriatic arthritis therapies
  • Biological response modifiers
03 Autoimmune Disorders

Groundbreaking trials investigating treatments for various autoimmune conditions, including Sjögren's disease and systemic sclerosis. Research focuses on novel therapeutic approaches and long-term disease management strategies.

  • Innovative antibody treatments
  • Disease-modifying therapies
  • Immunological interventions
Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.